Cera and uMed Announce New Partnership

Key Takeaways

• Cera’s network provides real‑time data from 2.5M monthly home visits
• uMed handles ethical outreach and digital consent for home trials
• Partnership targets housebound and frail seniors, boosting trial diversity
• Enables GDPR‑compliant, decentralized trials without disrupting routine care

Pulse Analysis

Decentralised clinical trials have emerged as a strategic response to long‑standing enrollment bottlenecks, especially for older adults who face mobility constraints. Studies show that distance to research sites and poor mobility are the top two obstacles for patients over 65, leading to under‑representation of this high‑need group. By shifting screening and consent processes to the home, sponsors can capture a broader, more heterogeneous population, improving the external validity of efficacy and safety data while reducing the time and cost associated with site‑based recruitment.

The Cera‑uMed alliance exemplifies how health‑tech infrastructure can be repurposed for research. Cera’s extensive home‑care workforce generates granular, real‑time health metrics across millions of visits, creating a ready‑made pool of potential participants. uMed’s regulated platform adds a compliant digital layer for outreach, consent, and longitudinal data capture, ensuring GDPR adherence and ethical standards. Together they create a seamless "last‑mile" recruitment pipeline that respects patients’ daily routines, minimizes disruption, and accelerates enrollment for life‑science organisations seeking to include frail, multi‑morbid cohorts.

For the broader life‑sciences ecosystem, this model signals a shift toward patient‑centric trial design. Companies that integrate home‑based recruitment can expect faster enrolment, richer real‑world evidence, and a competitive edge in developing therapies for an aging population. As regulators increasingly endorse decentralized approaches, partnerships like Cera and uMed are likely to become templates for scaling inclusive research, ultimately delivering medicines that reflect the needs of the most vulnerable patients.